Assessment of socio-economic availability of spironolactone diuretics (C03DA01) and furosemide (C03CA01) of the domestic pharmaceutical market


  • I. O. Fedyak Ivano-Frankivsk National Medical University, Ukraine
  • O. V. Maksymenko Ivano-Frankivsk National Medical University, Ukraine



marketing analysis, monthly market monitoring, diuretics of the spironolactone group (C03DA01) and furosemide (C03CA01), cirrhosis, ascites


The results of market monitoring of diuretics recommended for the treatment of liver cirrhosis complications have been analyzed in the article. From 01/01/2017 till 31/12/2018 a monthly monitoring of the physical and socio-economic availability for domestic patients with ascites was performed.

Aim. To interpret the dynamics of data of the marketing analysis of medicines recommended for the treatment of patients with liver cirrhosis and its most common complication – ascites.

Materials and methods. Marketing analysis carried out by the method of monthly monitoring of the range, average wholesale and selling prices, indicators of socio-economic availability (price liquidity ratios, adequacy of solvency of the population, , availability (D) of medicines) according to the data “The software complex “Apteka” resource ( for the period of 01.01.2017-31.12.2018.

Results. It has been found out that diuretics of spironolactone (C03DA01) and furosemide (C03CA01) groups are sufficiently represented at the domestic pharmaceutical market; their socio-economic availability has shown a positive dynamics. Among the medicines of spironolactone the lowest wholesale and retail price was for Spironolacton-Darnitsa, PrAS FF “Darnitsa”, while the highest price was for Veroshpiron, Gedeon Richter; among the medicines of furosemide – for Furosemid, LTD RP “GNSSLS” and Lazyx, “Sanofi India Limited”, respectively. A sharp reduction in prices for some drugs was due to the inclusion of active substances in the Government program “Available medicines”, and the period of decline in cost coincided with the time of their introduction into the Register of Medicines, which cost was subjected to compensation. As for range in prices, they were due to the fluctuation of the hryvnia against the dollar in 2017-2018.

Conclusions. The assessment of the social-economic availability of diuretics of the spironolactone and furosemide groups by monitoring of the liquidity ratios (Cliq), adequacy of the population’s solvency (Сa.s), availability (D) of medicines allows them to be considered financially affordable for an average inhabitant suffering from ascites because of liver cirrhosis. The market window for the future domestic medicine based on the combination of spironolactone and furosemide (100 mg + 40 mg, respectively) has been identified, it is expected to have a price advantage over the imported analog.

Author Biographies

I. O. Fedyak, Ivano-Frankivsk National Medical University

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Organization and Economics of Pharmacy
and Drug Technology

O. V. Maksymenko, Ivano-Frankivsk National Medical University

teaching assistant of the Department of Organization and Economics of Pharmacy and Drug Technology


Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) tretynnoi (vysokospetsializovannoi) medychnoi dopomohy “Tsyroz pechinky ta yoho uskladnennia” (proekt). (2016). Available at:

Tsyroz pechinky ta yoho uskladnennia: klinichna nastanova (2017). Available at:

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. (2010). Journal of Hepatology, 53 (3), 397–417. doi: 10.1016/j.jhep.2010.05.004.

Angeli, P., Fasolato, S., Mazza, E. et al. (2010).Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Gut, 59 (1), 98–104. doi: 10.1136/gut.2008.176495.

Runyon, B. A. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis: Update 2012. (2012). Available at:

Nemchenko, A. S., Kosiachenko, K. L., Kovalenko, O. V., Kubarieva, I. V. (2011). Metodychni rekomendatsii z provedennia monitorynhu tsin na likarski zasoby, shcho zakupovuiutsia za derzhavnymy tsilovymy prohramamy. Kharkiv: Vyd–vo NFaU, 17.

Nemchenko, A. S., Kosiachenko, K. L., Nemchenko, O. A. (2012). Tsinoutvorennia na likarski zasoby. (2nd ed.). Kharkiv: FOP Vyrovets A. P.: Apostrof, 304.

Hermanok, T. A., Ivko, T. I. (2014). Metodolohiia marketynhovykh, farmakoepidemiolohichnykh ta farmakoekonomichnykh doslidzhen. Vinnytsia: Nilan–LTD, 64.

Tykhonov, O. I., Bohdan, N. S., Shpychak, O. S. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4, 78–89. doi: 10.24959/uekj.16.38.

Kotvitska, A. A. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 5, 41–46.

Slobodianiuk, M. M., Baihush, Yu. V. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 1, 72–79. doi: 10.24959/uekj.16.7.

Poluichak, N. Yu., Demchuk, M. B., Yur’ieva, O. O., Hroshovyi, T. A. (2015). Farmatsevtychnyi chasopys, 3, 34–39.

Iakovlieva, L. V., Portianka, M. M., Kyrychenko, O. M. (2016). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy: materialy naukovoho sympoziumu u ramkakh VIII Natsionalnoho zizdu farmatsevtiv Ukrainy (15–16 veresnia 2016). (p. 141). Kharkiv.

Nemchenko, A. S., Kurylenko, Yu. Ye. (2018). Farmatsevtychnyi chasopys, 2, 77–81.

Nemchenko, A. S., Balynska, M. V. (2017). Sotsialna farmatsiia v okhoroni zdorov’ia, 3 (2), 70–79. doi: 10.24959/sphhcj.17.75.

Fediak, I. O., Bilyk, I. P. (2018). Sotsialna farmatsiia v okhoroni zdorov’ia, 4 (1), 72–82. doi: 10.24959/sphhcj.18.106.





Health organization